European disparities in access to cancer drugs
New research has highlighted stark disparities in access to the latest cancer drugs across European Union nations, according to data presented at the 33rd Congress of the European Society for Medical Oncology (ESMO) in Stockholm. While countries like France, Spain, Austria and Switzerland have tended to introduce the new drugs quickly, researchers say, others such as the UK and more recent EU entrants bring them in more slowly.
Dr Nils Wilking from the Karolinska Institute in Sweden gathered data on the sales of newer drugs per inhabitant of each country provided by pharmaceutical industry consultants IMS Health. His group's focus was on the uptake of newer 'targeted' drugs over the past 10 years in 27 countries.
Overall, they found substantial variation between countries, both in terms of speed and uptake of newer cancer drugs, and the level of usage of the drugs.
"Of the major western EU countries, the UK tends to come out both low and slow with a few exceptions," Dr Wilking said. "Overall, Austria, Switzerland and France bring the new drugs out more quickly. France also has an especially high general uptake of most new drugs. Spain is somewhat lower and slower but was a 'leader' in the early part of the 2000s."
The cost of the newer drugs is probably the major barrier to access, Dr. Wilking said. "To some extent it could also relate to the introduction of more 'targeted' drugs that tend to be more complex to understand and, in some cases, have smaller studies to support their approval."
The impact of this disparity on the health of Europe's cancer patients is hard to say with certainty, Dr Wilking said. "It is a complicated area as the epidemiological data lags so much behind. We need much better epidemiological data in order to evaluate the link between access to cancer drugs and outcome."
Access to drugs is not the only factor involved in improving cancer outcomes, he added. "Patients need to have full access to the most innovative technologies in prevention, screening, surgery, radiotherapy and drugs."
Source: European Society for Medical Oncology
Articles on the same topic
- New drug substantially extends survival in pancreatic cancerTue, 16 Sep 2008, 14:44:35 UTC
- Study establishes role for gefitinib in Asian nonsmokers with lung cancerTue, 16 Sep 2008, 14:44:17 UTC
- Promising new treatment option for women with recurrent ovarian cancerMon, 15 Sep 2008, 15:17:00 UTC
- Investigational drug shows promise in ovarian cancerMon, 15 Sep 2008, 14:29:29 UTC
- Ovarian cancer drug trial reveals promising new treatmentMon, 15 Sep 2008, 14:29:17 UTC
Other sources
- New Drug Substantially Extends Survival In Pancreatic Cancerfrom Science DailyWed, 17 Sep 2008, 19:14:24 UTC
- Investigational drug shows promise in ovarian cancerfrom Biology News NetWed, 17 Sep 2008, 12:14:41 UTC
- New ovarian cancer treatment is developedfrom UPITue, 16 Sep 2008, 19:07:12 UTC
- New drug substantially extends survival in pancreatic cancerfrom PhysorgTue, 16 Sep 2008, 14:43:28 UTC
- Investigational drug shows promise in ovarian cancerfrom Biology News NetMon, 15 Sep 2008, 22:21:58 UTC
- Hope, confusion in hunt for ovarian cancer testsfrom PhysorgMon, 15 Sep 2008, 20:28:33 UTC
- Hope, confusion in hunt for ovarian cancer testsfrom AP HealthMon, 15 Sep 2008, 19:42:56 UTC
- Investigational drug shows promise in ovarian cancerfrom PhysorgMon, 15 Sep 2008, 15:14:57 UTC
- Ovarian Cancer Drug Trial Reveals Promising New Treatmentfrom Science DailyMon, 15 Sep 2008, 14:28:18 UTC
- Investigational Drug Shows Promise In Ovarian Cancerfrom Science DailyMon, 15 Sep 2008, 14:28:12 UTC